LIVN · NASDAQ
LivaNova PLC
$79.90 -0.17 (-0.21%)
Company overview
LivaNova PLC is a medical device company that designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, and other related products. The Neuromodulation segment designs, develops, and markets the VNS Therapy System, an implantable device that delivers vagus nerve stimulation therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS.
- Sector
- Healthcare
- Industry
- Medical - Devices
- Exchange
- NASDAQ
- Market cap
- $4.4B
- Employees
- 2,900
- Headquarters
- London
- Website
- livanova.com
- CEO
- Vladimir A. Makatsaria
- Listed
- October 19, 2015
- P/E
- 40.56
- Dividend yield
- 0.00%
Company financials
- Revenue
- $1.4B
- Gross profit
- $969M
- Operating income
- $203M
- EBITDA
- $233M
- Net income
- $107M
- EPS
- $1.97
- Total assets
- $2.5B
- Total debt
- $335M
- Gross margin
- 67.57%
- Net margin
- 7.47%
- Earnings yield
- 2.47%
Showing FY 2025
LIVN
1D
NASDAQ
O80.40H81.90L79.52C80.07-0.14 (-0.17%)Vol662.98K
News